Intraoperative hypotension is associated with shortened overall survival after lung cancer surgery

BMC Anesthesiology

Table 2 Association between different threshold and duration of intraoperative hyper−/hypotension and overall survival

Thresholds	N	Episode duration of ≥5 min		N	Episode duration of ≥10 min
Thresholds	N	Unadjusted HR (95% CI) ^a	Adjusted HR (95% CI) ^a,b	N	Unadjusted HR (95% CI) ^a	Adjusted HR (95% CI) ^a,b
Intraoperative SBP > 160 mmHg	101	1.132 (0.841–1.532)	1.371 (0.974–1.929)	50	1.064 (0.714–1.584)	1.516 (0.980–2.343)
Intraoperative SBP > 140 mmHg	286	0.671 (0.526–0.854)	0.719 (0.545–0.948)	201	0.687 (0.532–0.887)	0.795 (0.594–1.063)
Intraoperative SBP < 100 mmHg	279	1.371 (1.072–1.754)	1.382 (1.047–1.825)	201	1.084 (0.846–1.387)	1.118 (0.840–1.488)
Intraoperative SBP < 90 mmHg	73	0.993 (0.701–1.406)	0.903 (0.613–1.330)	46	1.111 (0.736–1.679)	1.040 (0.652–1.660)

Abbreviations: N number of patients with events, HR hazard ratio, CI confidence interval, SBP systolic blood pressure. Results in bold indicate those with p < 0.05
^a Performed with COX proportional-hazards regression analyses
^b Adjusted for age, body mass index, male gender, chronic smoking, history of hypertension, preoperative chemotherapy, perioperative sufentanil equivalent, perioperative dexamethasone, perioperative flurbiprofen axetil, intraoperative blood transfusion, conservative resection/biopsy (vs. other types of surgery), mediastinal lymph node dissection, small cell lung cancer, tumor differentiation, pathological Tumor-Node-Metastasis stage, occurrence of postoperative complications, and postoperative chemo−/radiotherapy. Maximal tumor size was excluded due to correlation with pathological Tumor-Node-Metastasis stage

ISSN: 1471-2253